Segment Reporting (Tables)

12 Months Ended

Dec. 31, 2024

Segment Reporting

Schedule of information about the Company's single segment

	Year Ended December 31,
	2024		2023		2022
Revenue	$	63,723	$	58,443	$	51,494
Cost of Product Revenue		5,626		5,281		4,540
Research & Development (a)
Direct Program Expenses
AXPAXLI for wet AMD		57,507		8,750		5,296
Other clinical and preclinical programs		8,099		11,191		7,892
Unallocated expenses
Personnel costs		28,625		22,617		20,854
All other costs		16,236		5,720		8,510
Selling & Marketing (a)		38,029		36,564		34,920
General & Administrative (a)		38,861		23,838		23,766
Facilities (b)		5,626		6,056		5,297
Stock-based compensation		33,109		17,825		16,964
Depreciation		3,786		2,983		2,109
Interest income		20,282		3,983		798
Interest expense		(13,577)		(11,338)		(7,022)
Other non-operating items		(28,430)		9,001		13,840
Net Loss	$	(193,506)	$	(80,736)	$	(71,038)

(a) excluding stock-based compensation, depreciation, and facilities expenses

(b) excluding stock-based compensation and depreciation